Human papillomavirus (HPV) causes cervical cancer in half a million women each year, and
two genotypes, 16 and 18, account for about 70% of all cervical cancers worldwide. 1 Two …

Cervical cancer is the second leading cause of death from cancer in women worldwide.
Since the introduction of Papanicolaou smear-based screening in the 1950s, mortality from …

The discovery of human papillomavirus (HPV) DNA in cervical cancer by Harald zur Hausen
sparked 30 years of research that established that persistent cervical infection by certain …

It took almost 10 years from the discovery of an association between human papillomavirus
(HPV) and cervical cancer 1 to the finding of HPV type 16 in cervical cancer tissue. 2 It took …

Vaccines have repeatedly proven successful in the fight against infectious diseases,
bringing some equity in health care to even the least developed regions of the world …

After prophylactic human papillomavirus (HPV) vaccina tion, cost-effectiveness models
predict that a reduction in cervical cancer will occur decades from now, but only when 90 …

In a pair of articles in The Lancet Oncology, Lehtinen and colleagues1 and Wheeler and
colleagues2 present 4-year end-of-study data from a trial of a prophylactic human …

In The Lancet Oncology, Hitt Sharma and colleagues1 report findings from a pivotal phase
2/3 human papillomavirus (HPV) prophylactic vaccine trial. Briefly, they show that two doses …

Nearly all cervical cancer and its precursor lesions are thought to arise from infection with
one of the human papillomavirus (HPV) types. 1 These viruses infect skin and mucosae …

Background Prophylactic human papillomavirus (HPV) vaccines have to provide sustained
protection. We assessed efficacy, immunogenicity, and safety of the HPV-16/18 AS04 …